GlaxoSmithKline (GSK) S.R.L. Sustainability Profile
GlaxoSmithKline S.R.L., commonly referred to as GSK, is a prominent global healthcare company headquartered in Romania (RO). Established in 2000, GSK has made significant strides in the pharmaceutical and consumer healthcare industries, focusing on innovative medicines, vaccines, and consumer health products. With a strong presence in Europe and other major operational regions, GSK is renowned for its commitment to research and development, leading to groundbreaking treatments in areas such as respiratory diseases, HIV, and vaccines. The company’s core offerings, including its unique portfolio of prescription medications and over-the-counter products, underscore its dedication to improving patient outcomes. GSK's market position is bolstered by its notable achievements in public health, making it a trusted name in the industry. Through continuous innovation and a patient-centric approach, GSK remains at the forefront of healthcare solutions.
DitchCarbon Score
How does GlaxoSmithKline (GSK) S.R.L.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
GlaxoSmithKline (GSK) S.R.L.'s score of 100 is higher than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
GlaxoSmithKline (GSK) S.R.L., headquartered in Romania, currently does not report specific carbon emissions data, as no emissions figures are available. The company is a current subsidiary of GSK plc, which cascades its climate commitments and initiatives down to its subsidiaries. GSK plc has set ambitious climate targets, including commitments to reduce greenhouse gas emissions across its operations. These initiatives are part of a broader strategy to achieve net-zero emissions by 2030 for its own operations (Scope 1 and 2) and by 2045 for its value chain (Scope 3). The company actively participates in various climate initiatives, including the Science Based Targets initiative (SBTi), the Carbon Disclosure Project (CDP), and the RE100 initiative, all of which are cascaded to GSK S.R.L. at a second level. While specific reduction targets for GSK S.R.L. are not detailed, the overarching goals from GSK plc reflect a strong commitment to sustainability and climate action. The absence of direct emissions data highlights the need for ongoing transparency and accountability in reporting environmental impacts.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 1,040,928,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 788,149,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 16,630,521,000 | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | - |
How Carbon Intensive is GlaxoSmithKline (GSK) S.R.L.'s Industry?
How Carbon Intensive is GlaxoSmithKline (GSK) S.R.L.'s Location?
GlaxoSmithKline (GSK) S.R.L.'s Scope 3 Categories Breakdown
GlaxoSmithKline (GSK) S.R.L.'s Scope 3 emissions, which decreased by 0% last year and decreased by approximately 46% since 2013, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Use of Sold Products" being the largest emissions source at 56% of Scope 3 emissions.
Top Scope 3 Categories
GlaxoSmithKline (GSK) S.R.L.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
GlaxoSmithKline (GSK) S.R.L. has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Novartis Pharma Services Romania S.R.L.
Let us know if this data was useful to you
Usage Policy
You're welcome to quote or reference data from this page, but please include a visible link back to this URL.
Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.